• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

mrosenthal@unimelb.edu.au

Credentials


Position
Honorary (Professorial Fellow)
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0003-1152-6764

Prof Mark Rosenthal

Honorary (Professorial Fellow)
The Sir Peter MacCallum Department of Oncology

256 Scholarly works
7 Projects

HIGHLIGHTS

  • 2025

    Journal article

    Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial
    DOI: 10.1038/s41591-025-03884-4
  • 2023

    Journal article

    Australian genome-wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26
    DOI: 10.1093/neuonc/noac279
  • 2022

    Research grants (other domestic)

    The COMET (Community Supportive Care Trials) Program: Enhancing Supportive Care Trials for Community Dwelling People With Cancer
  • 2022

    Research Grant

    The COMET (Community Supportive Care Trials) Program: Enhancing Supportive Care Trials For Community Dwelling People With Cancer
  • 2021

    Research grants (ARC, NHMRC, MRFF)

    Targeted Therapies for Vascular Malformations
  • 2019

    Journal article

    A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2– positive metastatic breast cancer
    DOI: 10.1158/2159-8290.CD-18-1151
  • 2012

    Journal article

    Glutamate is associated with a higher risk of seizures in patients with gliomas
    DOI: 10.1212/WNL.0b013e318266fa89
Mark Rosenthal

RECENT SCHOLARLY WORKS

  • 2025

    Journal article

    First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma
    DOI: 10.1093/noajnl/vdaf160
  • 2024

    Journal article

    A PERIOPERATIVE STUDY OF SAFUSIDENIB IN PATIENTS WITH IDH1 MUTATED GLIOMA
    DOI: 10.1093/neuonc/noae165.0382
  • 2024

    Journal article

    443O A perioperative study of safusidenib in patients with IDH1 mutated glioma
    DOI: 10.1016/j.annonc.2024.08.513
  • 2024

    Journal article

    Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)
    DOI: 10.1007/s11060-024-04668-5
  • 2024

    Journal article

    A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma
    DOI: 10.1007/s11060-023-04513-1
  • 2024

    Journal article

    A perioperative study of Safusidenib in patients with IDH1-mutated glioma
    DOI: 10.1080/14796694.2024.2383064
  • 2023

    Journal article

    Developing and validating a multi-criteria decision analytic tool to assess the value of cancer clinical trials: evaluating cancer clinical trial value
    DOI: 10.1186/s12962-023-00496-y
  • 2023

    Journal article

    Assessing neuro-oncology clinical trial impact and value: Testing a novel multi-criteria decision analysis app
    DOI: 10.1016/j.jocn.2023.07.024

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224